Cullinan oncology licenses u.s. rights to the first clinical-stage b7h4 x 4-1bb bispecific immune activator from harbour biomed

Cambridge, mass., feb. 13, 2023 (globe newswire) -- cullinan oncology, inc. (nasdaq: cgem) and harbour biomed (hkex: 02142) today announced that cullinan oncology has entered into an exclusive license with harbour biomed for the development and commercial rights of hbm7008 (cln-418) in the u.s. cln-418/hbm7008 is a b7h4 x 4-1bb bispecific immune activator developed from next-gen heavy chain only antibody (hcab)-based multi-specific antibody discovery platform hbice®, currently in a phase 1 clinical study being conducted at u.s. and australian sites in patients with advanced solid tumors.
CGEM Ratings Summary
CGEM Quant Ranking